These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
49. Intravitreal Bevacizumab in Diabetic Retinopathy. Recommendations from the Pan-American Collaborative Retina Study Group (PACORES): The 2016 Knobloch Lecture. Arevalo JF; Liu TYA; Asia Pac J Ophthalmol (Phila); 2018; 7(1):36-39. PubMed ID: 29280367 [TBL] [Abstract][Full Text] [Related]
50. Management paradigms for diabetic macular edema. Mitchell P; Wong TY; Am J Ophthalmol; 2014 Mar; 157(3):505-13.e1-8. PubMed ID: 24269850 [TBL] [Abstract][Full Text] [Related]
51. Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. Mason JO; Nixon PA; White MF Am J Ophthalmol; 2006 Oct; 142(4):685-8. PubMed ID: 17011869 [TBL] [Abstract][Full Text] [Related]
52. Repeated intravitreal bevacizumab (Avastin(®)) treatment of persistent new vessels in proliferative diabetic retinopathy after complete panretinal photocoagulation. Schmidinger G; Maar N; Bolz M; Scholda C; Schmidt-Erfurth U Acta Ophthalmol; 2011 Feb; 89(1):76-81. PubMed ID: 21272288 [TBL] [Abstract][Full Text] [Related]
53. Treating maculopathy at the expense of proliferative disease: an emerging problem in 'macular treatment centres'. Mookhtiar MA; Carrim ZI Eye (Lond); 2014 Nov; 28(11):1390-1. PubMed ID: 25081293 [No Abstract] [Full Text] [Related]
54. Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti-Vascular Endothelial Growth Factor Treatment: Outcomes from the Phase 3 Program. Do DV; Nguyen QD; Vitti R; Berliner AJ; Gibson A; Saroj N; Soo Y; Boyer DS Ophthalmology; 2016 Apr; 123(4):850-7. PubMed ID: 26832658 [TBL] [Abstract][Full Text] [Related]
55. Angiogenic and inflammatory markers in the intraocular fluid of eyes with diabetic macular edema and influence of therapy with bevacizumab. Funk M; Schmidinger G; Maar N; Bolz M; Benesch T; Zlabinger GJ; Schmidt-Erfurth UM Retina; 2010 Oct; 30(9):1412-9. PubMed ID: 20711086 [TBL] [Abstract][Full Text] [Related]
57. [Treatment of diabetic macular oedema with the VEGF inhibitors ranibizumab and bevacizumab: conclusions from basic in vitro studies]. Lang GE; Lang GK; Deissler HL Klin Monbl Augenheilkd; 2014 May; 231(5):527-34. PubMed ID: 24799173 [TBL] [Abstract][Full Text] [Related]
58. Agreement between clinician and reading center gradings of diabetic retinopathy severity level at baseline in a phase 2 study of intravitreal bevacizumab for diabetic macular edema. Scott IU; Bressler NM; Bressler SB; Browning DJ; Chan CK; Danis RP; Davis MD; Kollman C; Qin H; Retina; 2008 Jan; 28(1):36-40. PubMed ID: 18185135 [TBL] [Abstract][Full Text] [Related]
59. Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema. Kumar V; Ghosh B; Raina UK; Goel N Acta Ophthalmol; 2010 Mar; 88(2):e3; author reply e4. PubMed ID: 19549100 [No Abstract] [Full Text] [Related]
60. Rapid resolution of severe retinal neovascularisation in proliferative diabetic retinopathy following adjunctive intravitreal bevacizumab (Avastin). Thew M Clin Exp Optom; 2009 Jan; 92(1):34-7. PubMed ID: 19125745 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]